Zeng Zifeng, Luo Rongtai, Lan Xinping
Center for Cardiovascular Diseases, Meizhou Academy of Medical Sciences, Meizhou People's Hospital, Meizhou, People's Republic of China.
Guangdong Provincial Engineering and Technology Research Center for Molecular Diagnostics of Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, People's Republic of China.
Int J Gen Med. 2025 Aug 18;18:4549-4562. doi: 10.2147/IJGM.S532170. eCollection 2025.
The renal safety and cardiovascular outcomes of intra-aortic balloon pump (IABP) support during percutaneous coronary intervention (PCI) in patients with renal dysfunction remain controversial.
To investigate the effects of IABP on renal function and major adverse cardiovascular events (MACEs) in PCI patients with renal dysfunction, and to establish an individualized prognostic prediction model.
In this retrospective cohort study, 253 PCI patients with renal dysfunction from Meizhou People's Hospital (January-December 2023) were analyzed. Propensity score matching (1:4 IABP/non-IABP) balanced baseline characteristics. Least absolute shrinkage and selection operator (LASSO) regression identified predictors for MACEs, followed by nomogram development and validation.
Post-matching (IABP = 16, non-IABP = 64), despite higher baseline risk in the IABP group, no intergroup differences occurred in postoperative creatinine, eGFR, or MACEs incidence (all >0.05). However, this group exhibited greater eGFR decline from baseline. Multivariate analysis identified five independent MACEs predictors: preoperative B-type natriuretic peptide (BNP), postoperative BNP, preoperative neutrophil-to-lymphocyte ratio (NLR), postoperative blood urea nitrogen (BUN), and prealbumin levels. The prediction model achieved AUCs of 0.869 (: 0.774-0.964) and 0.843 (: 0.678-1.000) in training and validation sets, with decision curve analysis confirming clinical utility at 10%-80% risk thresholds.
IABP may exacerbate subclinical renal injury in PCI patients with renal dysfunction without mitigating MACEs risk. The validated nomogram provides individualized risk stratification to guide clinical management.
肾功能不全患者在经皮冠状动脉介入治疗(PCI)期间使用主动脉内球囊泵(IABP)支持的肾脏安全性和心血管结局仍存在争议。
探讨IABP对肾功能不全PCI患者肾功能及主要不良心血管事件(MACE)的影响,并建立个体化预后预测模型。
在这项回顾性队列研究中,分析了梅州市人民医院2023年1月至12月的253例肾功能不全PCI患者。倾向评分匹配(IABP/非IABP为1:4)平衡了基线特征。最小绝对收缩和选择算子(LASSO)回归确定了MACE的预测因素,随后进行列线图的开发和验证。
匹配后(IABP组 = 16例,非IABP组 = 64例),尽管IABP组基线风险较高,但术后肌酐、估算肾小球滤过率(eGFR)或MACE发生率组间无差异(均>0.05)。然而,该组eGFR较基线下降更大。多变量分析确定了五个独立的MACE预测因素:术前B型利钠肽(BNP)、术后BNP、术前中性粒细胞与淋巴细胞比值(NLR)、术后血尿素氮(BUN)和前白蛋白水平。预测模型在训练集和验证集中的曲线下面积(AUC)分别为0.869(95%可信区间:0.774 - 0.964)和0.843(95%可信区间:0.678 - 1.000),决策曲线分析证实了在10% - 80%风险阈值下的临床实用性。
IABP可能会加重肾功能不全PCI患者的亚临床肾损伤,而不会降低MACE风险。经过验证的列线图提供了个体化风险分层,以指导临床管理。